Journal of Asthma and Allergy
Volume 17, 2024 - Issue
Open access
276
Views
0
CrossRef citations to date
0
Altmetric
REVIEW
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types
Reynold Panettieri Jr1 Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0003-0834-4636View further author information
, https://orcid.org/0000-0003-0834-4636View further author information
Njira Lugogo2 Michigan Medicine Asthma Program, University of Michigan, Ann Arbor, MI, USAhttps://orcid.org/0000-0002-0235-7105View further author information
, Jonathan Corren3 Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USAhttps://orcid.org/0000-0001-5951-3239View further author information
& Christopher S Ambrose4 AstraZeneca, Gaithersburg, MD, USAhttps://orcid.org/0000-0003-4175-7336View further author information
Pages 219-236
|
Received 27 Oct 2023, Accepted 23 Feb 2024, Published online: 18 Mar 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.